These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 12564784)

  • 41. Comparison of the tolerability of an acellular pertussis-containing vaccine given as the fifth booster dose in differently primed children.
    Kemmeren JM; Timmer SS; van der Maas NA; de Melker HE
    Vaccine; 2011 Jun; 29(26):4373-7. PubMed ID: 21514347
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed Infanrix hexa.
    Vesikari T; Rivera L; Korhonen T; Ahonen A; Cheuvart B; Hezareh M; Janssens W; Mesaros N
    Hum Vaccin Immunother; 2017 Jul; 13(7):1505-1515. PubMed ID: 28340322
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Simultaneous administration of meningococcal C conjugate vaccine and diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in children: a randomized double-blind study.
    Halperin SA; McDonald J; Samson L; Danzig L; Santos G; Izu A; Smith B; MacDonald N
    Clin Invest Med; 2002 Dec; 25(6):243-51. PubMed ID: 12516995
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunogenicity and reactogenicity of Infanrix™ when co-administered with meningococcal MenACWY-TT conjugate vaccine in toddlers primed with MenHibrix™ and Pediarix™.
    Leonardi M; Latiolais T; Sarpong K; Simon M; Twiggs J; Lei P; Rinderknecht S; Blatter M; Bianco V; Baine Y; Friedland LR; Baccarini C; Miller JM
    Vaccine; 2015 Feb; 33(7):924-32. PubMed ID: 25305567
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunogenicity and reactogenicity of a three-dose primary vaccination course with a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-haemophilus influenzae type b vaccine coadministered with a meningococcal C conjugate vaccine.
    Tejedor JC; Omeñaca F; García-Sicilia J; Verdaguer J; Van Esso D; Esporrín C; Molina V; Muro M; Marés J; Enrubia M; Moraga F; García-Corbeira P; Dobbelaere K; Schuerman L;
    Pediatr Infect Dis J; 2004 Dec; 23(12):1109-15. PubMed ID: 15626947
    [TBL] [Abstract][Full Text] [Related]  

  • 46. DTaP-IPV/Hib vaccine (Pentacel).
    Dhillon S; Keam SJ
    Paediatr Drugs; 2008; 10(6):405-16. PubMed ID: 18998751
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Humoral immunity of dTap-IPV vaccine (REPEVAX®) administered one month after dT-IPV vaccine (REVAXIS®) in adults with unknown vaccination history.
    Larnaudie S; Guiso N; Baptiste C; Desaint C; Desforges L; Lebon P; Soubeyrand B; Launay O
    Hum Vaccin; 2010 Oct; 6(10):829-34. PubMed ID: 20864810
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Simultaneous vaccination of Chinese applicants for a United States immigrant visa.
    Hua L; Hongtao H; Shunqin W; Jinping G; Jiandong C; Zhaoliang L; Xinwen F
    Travel Med Infect Dis; 2008 May; 6(3):130-6. PubMed ID: 18486068
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety and reactogenicity of DTPa-HBV-IPV/Hib and DTPa-IPV/I-Hib vaccines in a post-marketing surveillance setting.
    Lim FS; Phua KB; Lee BW; Quak SH; Teoh YL; Ramakrishnan G; Han HH; Van Der Meeren O; Jacquets JM; Bock HL
    Southeast Asian J Trop Med Public Health; 2011 Jan; 42(1):138-47. PubMed ID: 21323176
    [TBL] [Abstract][Full Text] [Related]  

  • 50. DTaP5-IPV-Hib-HepB, a hexavalent vaccine for infants and toddlers.
    Lee AW; Jordanov E; Boisnard F; Marshall GS
    Expert Rev Vaccines; 2017 Feb; 16(2):85-92. PubMed ID: 27996332
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine.
    Tejedor JC; Moro M; Ruiz-Contreras J; Castro J; Gómez-Campderá JA; Navarro ML; Merino JM; Martín-Ancel A; Roca J; García-del-Río M; Jurado A; Díez-Delgado FJ; Omeñaca F; García-Sicilia J; Boceta R; García-Corbeira P; Jacquet JM; Collard A; Schuerman L;
    Pediatr Infect Dis J; 2006 Aug; 25(8):713-20. PubMed ID: 16874171
    [TBL] [Abstract][Full Text] [Related]  

  • 52. DTPa-HBV-IPV vaccine for primary vaccination of infants.
    Nolan T; Lambert S; Roberton D; Marshall H; Richmond P; Streeton C
    J Paediatr Child Health; 2007 Sep; 43(9):587-92. PubMed ID: 17688642
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Kinrix: a new combination DTaP-IPV vaccine for children aged 4-6 years.
    Weston WM; Klein NP
    Expert Rev Vaccines; 2008 Nov; 7(9):1309-20. PubMed ID: 18980534
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined Haemophilus influenzae type b conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines.
    Shinefield H; Black S; Thear M; Coury D; Reisinger K; Rothstein E; Xu J; Hartzel J; Evans B; Digilio L; Schödel F; Brown ML; Kuter B;
    Pediatr Infect Dis J; 2006 Apr; 25(4):287-92. PubMed ID: 16567978
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antipolyribosyl ribitol phosphate response of premature infants to primary and booster vaccination with a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio virus/Haemophilus influenzae type b vaccine.
    Omeñaca F; Garcia-Sicilia J; García-Corbeira P; Boceta R; Torres V
    Pediatrics; 2007 Jan; 119(1):e179-85. PubMed ID: 17145903
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety and immunogenicity of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 3, 4, and 12-14 months of age.
    Halperin SA; Tapiero B; Diaz-Mitoma F; Law BJ; Hoffenbach A; Zappacosta PS; Radley D; McCarson BJ; Martin JC; Brackett LE; Boslego JW; Hesley TM; Bhuyan PK; Silber JL
    Vaccine; 2009 Apr; 27(19):2540-7. PubMed ID: 19124057
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A combined Haemophilus influenzae type B Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when coadministered with diphtheria, tetanus, acellular pertussis hepatitis B-inactivated poliovirus at 3, 5 and 11 months of age: results of an open, randomized, controlled study.
    Vesikari T; Forstén A; Desole MG; Ferrera G; Caubet M; Mesaros N; Boutriau D
    Pediatr Infect Dis J; 2013 May; 32(5):521-9. PubMed ID: 23190785
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    MMWR Recomm Rep; 1997 Mar; 46(RR-7):1-25. PubMed ID: 9091780
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Risk of febrile seizures and epilepsy after vaccination with diphtheria, tetanus, acellular pertussis, inactivated poliovirus, and Haemophilus influenzae type B.
    Sun Y; Christensen J; Hviid A; Li J; Vedsted P; Olsen J; Vestergaard M
    JAMA; 2012 Feb; 307(8):823-31. PubMed ID: 22357833
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Response of preterm newborns to immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B virus-inactivated polio and Haemophilus influenzae type b vaccine: first experiences and solutions to a serious and sensitive issue.
    Omeñaca F; Garcia-Sicilia J; García-Corbeira P; Boceta R; Romero A; Lopez G; Dal-Ré R
    Pediatrics; 2005 Dec; 116(6):1292-8. PubMed ID: 16322149
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.